COVID-19 Vaccine Updates: Vaccine May Enter in Indian Market, Epidemic Management in MBBS Course

COVID-19 vaccine latest Updates: Trial of COVID-19 vaccine is progressing very fast. Bernstein said in a report that the vaccine is expected to arrive by the first quarter of 2021 with approval in the Indian market. There are 4 candidates worldwide who can get approval by late 2020 or early 2021. India has access to two of these vaccines through the partnership, including AZ / Oxford’s viral Victor vaccine and Novavax’s protein subunit vaccine.

It states that phase I / II data is looking good in terms of safety and ability of the vaccine to get an immune response. It further states that they are optimistic that India will have an approved vaccine in the market by the first quarter of the calendar year 2021.

Challenge to implement a vaccination program

According to the report, where the vaccine can be made available for 3 to 6 US Dollars (225 to 550 rupees), Heard Immunity may come after two years due to the challenges of implementation. It has further been said that the experience of an adult vaccination program on a large scale is low.

The Polio Eradication Campaign in 2011 and the recent Intensified Mission Indradhanush (IMI) are examples of large-scale campaigns, but its scale is one-third higher than the demand for the program to implement the COVID-19 vaccine. It said that cold chain storage and trained manpower would be the biggest hurdles. Even estimating two times the present, it may take 18 to 20 months to implement the government program.

COVID-19: Corona’s highest effect in Delhi in people 5-17 years, revealed in Serological survey

The new module will prepare for an epidemic

On the other hand, medical students will now read about epidemic management. Now in MBBS course, it will be taught along with its social, legal and other aspects. India’s Chief Medical Regulator has introduced a new module to prepare doctors for the challenges faced by epidemics like COVID-19.

It is believed that the module of epidemic management will be from foundation course to final year. The Board of Governors of Medical Council of India (MCI) said that it will help India’s medical graduates to become such doctors and leaders in times of crisis in the event of an epidemic that serves humanity.

At the same time, in the race to find a cure for coronavirus infection, Baler College of Medicine (BCM) based in Texas has tied up with the Indian pharmaceutical company Biological E Limited to develop a safe, effective and affordable vaccine. According to BCM, BE headquartered in Hyderabad has licensed COVID-19 vaccine candidate developed at Baylor.

Source: www.financialexpress.com